2-cyclopropyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid methyl ester | 862695-73-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-cyclopropyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid methyl ester
• 英文别名: methyl 2-cyclopropyl-6-oxo-1H-pyridine-3-carboxylate
• CAS: 862695-73-6
• 化学式: C₁₀H₁₁NO₃
• 分子量: 193.202
• InChiKey: PLKAMOWQIMRCNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-cyclopropyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid methyl ester 在 二氯磷酸苯酯 、 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 3.17h， 生成 6-氯-2-环丙基烟酸
  参考文献：
  名称：

  Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors

  摘要：

  11 beta-HSD1 is increasingly seen as an attractive target for the treatment of type II diabetes and other elements of the metabolic syndrome. In this program of work we describe how a series of neutral 2-thioalkyl-pyridine 11 beta-HSD1 inhibitors were optimized in terms of their pharmacokinetic properties to give compounds with excellent bioavailability in both rat and dog through a core change to pyrimidine. A potential reactive metabolite issue with 4-thioalkyl-pyrimidines was circumvented by a switch from sulfur to carbon substitution. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.070
• 作为产物：
  描述：

  3-amino-3-cyclopropyl-acrylic acid methyl ester 在 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 50.0h， 生成 2-cyclopropyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid methyl ester
  参考文献：
  名称：

  Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors

  摘要：

  11 beta-HSD1 is increasingly seen as an attractive target for the treatment of type II diabetes and other elements of the metabolic syndrome. In this program of work we describe how a series of neutral 2-thioalkyl-pyridine 11 beta-HSD1 inhibitors were optimized in terms of their pharmacokinetic properties to give compounds with excellent bioavailability in both rat and dog through a core change to pyrimidine. A potential reactive metabolite issue with 4-thioalkyl-pyrimidines was circumvented by a switch from sulfur to carbon substitution. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.070

文献信息

• [EN] PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS<br/>[FR] DERIVES DE PYRIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RECEPTEUR CB2
  申请人：GLAXO GROUP LTD

  公开号：WO2005080342A1

  公开（公告）日：2005-09-01

  The present invention relates to novel pyridine derivatives such as compounds of the formula (I) and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.

  本发明涉及新型吡啶衍生物，如式(I)化合物以及在治疗疾病，特别是通过大麻素2受体活性介导的疼痛方面使用这些化合物或其药物组合物。
• [EN] PYRIDINE DERIVATIVES AS CONNABINOID RECEPTOR MODULATORS<br/>[FR] DERIVES DE LA PYRIDINE UTILISES COMME MODULATEURS DU RECEPTEUR CANNABINOIDE
  申请人：GLAXO GROUP LTD

  公开号：WO2005075464A1

  公开（公告）日：2005-08-18

  The present invention relates to novel pyridine derivatives such as compounds of the formula (I): and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.

  本发明涉及新颖的吡啶衍生物，如式(I)的化合物，以及这些化合物或其药物组合物在治疗疾病中的应用，特别是通过大麻素2受体活性介导的疼痛。
• Pyridine Derivatives and Their Use as Cb2 Receptor Modulators
  申请人：Eatherton Andrew John

  公开号：US20080280868A1

  公开（公告）日：2008-11-13

  The present invention relates to novel pyridine derivatives such as compounds of the formula (I): and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.

  本发明涉及新型吡啶衍生物，例如式（I）化合物，以及使用这些化合物或其制药组合物治疗疾病，特别是由大麻素2受体活性介导的疼痛。
• Pyridine Derivatives as Connabinoid Receptor Modulators
  申请人：Giblin Gerard Martin Paul

  公开号：US20080280952A1

  公开（公告）日：2008-11-13

  The present invention relates to novel pyridine derivatives such as compounds of the formula (I): and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.

  本发明涉及新型吡啶衍生物，例如公式（I）所示的化合物，以及这些化合物或其制药组合物在治疗疾病，特别是通过大麻素2受体活性介导的疼痛方面的应用。
• PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1718613A1

  公开（公告）日：2006-11-08